Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Stoke Therapeutics, Inc.

STOKNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 3, 2026Accepted Aug 3, 2026, 4:48 PM EDTFiling CIK 1780088Accession 0001950047-26-007565
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
Stoke Therapeutics, Inc.
Issuer CIK
0001623526
SEC file number
001-38938
Phone
7814308200
Person for whose account securities are to be sold
BARUCH TICHO
Relationships to issuer
Officer
Street
45 Wiggins Ave
City
Bedford
State / country code
MA
Postal code
01730

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common20,967605,107.6262,281,65508/03/2026NASDAQMorgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name
Morgan Stanley Smith Barney LLC Executive Financial Services
Street
1 New York Plaza
Street (continued)
8th Floor
City
New York
State / country code
NY
Postal code
10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 2 reported rows
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common03/15/2026Restricted Stock UnitsIssuer13,772N03/15/2026N/A
Common08/01/2025Performance Stock UnitsIssuer7,195N08/01/2025N/A

Sales reported in the preceding three months

Sales reported in the preceding three months · 2 reported rows
SellerSecuritySale dateAmount soldGross proceeds
10b5-1 Sales for BARUCH S. TICHOCommon07/01/20267,228236,067.93
10b5-1 Sales for BARUCH S. TICHOCommon06/01/20261,79554,891.10

Seller — prior-sale row 1, entry 1

Name
10b5-1 Sales for BARUCH S. TICHO
Street
45 Wiggins Ave
City
Bedford
State / country code
MA
Postal code
01730

Seller — prior-sale row 2, entry 1

Name
10b5-1 Sales for BARUCH S. TICHO
Street
45 Wiggins Ave
City
Bedford
State / country code
MA
Postal code
01730

Prior-sale reporting

Nothing to report for the preceding three months
N

Notice signature

Notice date
08/03/2026
Signed
/s/ Baruch Ticho
Plan adoption dates
11/19/2025

Company context

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow us on LinkedIn.

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionOct 29, 2026
  2. 144 filingOct 21, 2026
  3. SCHEDULE 13G - filed by BIOTECHNOLOGY VALUE FUND L P regarding Stoke Therapeutics, Inc.Sep 30, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 25, 2026
  5. 4 filingAug 18, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.